Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Indoleamine 23 Dioxygenase 1 Drugs Development Market Overview
According to the recently published report ‘Indoleamine 2,3 Dioxygenase 1 – Drugs in Development, 2021’; Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 38 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) – Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.
The report ‘Indoleamine 2,3 Dioxygenase 1 – Drugs in Development, 2021’ outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 6, 1, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease, Metabolic Disorders and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer, Metastatic Melanoma, Colon Cancer, Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adrenal Gland Cancer, Alopecia, Breast Cancer, Cervical Cancer, Colon Carcinoma, Endometrial Cancer, Ependymoma, Gallbladder Cancer, Glioma, Gliosarcoma, Hematological Tumor, High-Grade Glioma, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medulloblastoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcopenia, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer and Urethral Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
– The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects
– The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics
Reasons to Buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Gerologix Inc
Guangzhou BeBetter Medicine Technology Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
IO Biotech ApS
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
Lumos Pharma Inc
Luye Pharma Group Ltd
Merck & Co Inc
Nammi Therapeutics Inc
Netherlands Translational Research Center BV
Orpheris Inc
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Secarna Pharmaceuticals GmbH & Co KG
Shanghai De Novo Pharmatech Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Syntekabio Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.